What's Happening?
GlycanAge, a company specializing in biological age testing through glycan analysis, is organizing a significant conference in Dubrovnik, Croatia, this June. The event marks 25 years of research into 'inflammaging,'
a concept that links chronic low-grade inflammation to biological aging and age-related diseases. The conference, co-organized with the Mayo Clinic as part of the International Society for Applied Biological Sciences (ISABS) series, will feature leading academics and clinicians. The scientific program will be headlined by Prof. Dr. Claudio Franceschi, who coined the term 'inflammaging.' GlycanAge aims to move chronic-inflammation testing into routine clinical practice, highlighting the potential of glycan-based markers to predict diseases like diabetes and heart conditions up to a decade before symptoms appear.
Why It's Important?
The conference represents a pivotal moment in the application of inflammaging research to clinical practice. By integrating glycan-based testing into routine healthcare, there is potential to significantly alter how age-related diseases are predicted and managed. This could lead to earlier interventions and lifestyle changes that prevent the onset of conditions such as diabetes and heart disease. The ability to detect disease risk well in advance could transform preventive healthcare, reducing long-term healthcare costs and improving patient outcomes. GlycanAge's global reach, with operations in 64 markets, underscores the potential for widespread adoption of this technology, which could influence healthcare practices worldwide.
What's Next?
Following the conference, GlycanAge plans to expand its global presence further, with new facilities in India to enhance its coverage in Asia. The company is also focused on increasing the reliability and accessibility of its testing methods. As the conference aims to integrate glycan-based markers into clinical practice, the next steps will likely involve collaborations with healthcare providers and regulatory bodies to establish guidelines and protocols for their use. The outcomes of this conference could lead to increased investment in glycan research and development, potentially spurring innovation in the field of longevity science.
